Seminars in Liver Disease

LinksSchließen

Referenz

Zhu AX, Kang Y-K, Yen C-J. , et al; REACH-2 Study Investigators.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol 2019;
20 (02) 282-296

Bibliographische Angaben herunterladen

Aufrufen in: